ADMA Biologics
BiotechADMA Biologics is a biotechnology company focused on Infectious Disease. Key products include Bivigam.
ADMA Biologics's Key Drugs
ADMA Biologics's core commercial portfolio centers on Bivigam, Asceniv, spanning Infectious Disease — its most strategically important drugs approved in the last 15 years.
ADMA Biologics's Recent FDA Approvals
New NDA/BLA approvals for ADMA Biologics over the last two years — novel drugs only, excluding generics and label supplements.
ADMA Biologics's Therapeutic Areas
ADMA Biologics's approved drugs and pipeline span 1 therapeutic area, led by Infectious Disease, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ADMA Biologics's Top Competitors
ADMA Biologics's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ADMA Biologics Pipeline Snapshot
ADMA Biologics has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Bivigam leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2001-10-22
- Latest
- 2019-03-31
- Applications
- 3